publication venue for
- Omission of alcohol skin cleansing and risk of adverse events in long-term care residents undergoing COVID-19 vaccination: A cohort study. 20:2368681. 2024
- Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors. 19:2177066. 2023
- The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma. 19:2178217. 2023
- Cause and consequence of loss in vaccine trust. 15:628-629. 2019
- A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors. 13:1765-1767. 2017
- Considerations for the rational design of a Chlamydia vaccine. 13:831-835. 2017
- Economic evaluation of vaccines in Canada: A systematic review. 12:1257-1264. 2016
- Effects in the use of a genetically engineered strain ofLactococcus lactisdelivering in situ IL-10 as a therapy to treat low-grade colon inflammation. 10:1611-1621. 2014
- Safety, immunogenicity, and tolerability of three influenza vaccines in older adults. 9:2460-2473. 2013